Coherus BioSciences, Inc. (CHRS)
| Previous Close | 2.0600 |
| Open | 2.1200 |
| Bid | 2.1200 x 1800 |
| Ask | 2.1800 x 100 |
| Day's Range | 2.0300 - 2.1500 |
| 52 Week Range | 1.4300 - 8.2200 |
| Volume | |
| Avg. Volume | 2,463,698 |
| Market Cap | 242.318M |
| Beta (5Y Monthly) | 0.51 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.5300 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.43 |
GlobeNewswireCoherus to Report First Quarter 2024 Financial Results on May 9, 2024
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2024 financial results will be released after market close on Thursday, May 9, 2024. Starting at 5:00 p.m. EDT on May 9, 2024, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update. A webcast replay will be available on https://investors.coherus.com following the conclusion o
- GlobeNewswire
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
REDWOOD CITY, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) today announced the first presentation of clinical data for CHS-114, a highly selective cytolytic anti-CCR8 antibody, at the upcoming ASCO Annual Meeting, which will be held from May 31 to June 4, 2024, at McCormick Place in Chicago. Presentation Details Abstract: 2664Title: Preliminary Results of a Phase 1, First-in-human, Dose Escalation Study of the Anti-CCR8 Cytolytic Antibody, CHS-114
Simply Wall St.Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
